45 /100
MEDIUM RISK
Score updated Jul 14, 2026

DMAC — DiaMedica Therapeutics Inc. Dilution Risk Tracker

Track DMAC dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track DMAC — Get alerts when the score changes →

As of July 14, 2026, DiaMedica Therapeutics Inc. (DMAC) has a DilutionWatch DilutionScore of 45/100, rated MEDIUM dilution risk. DiaMedica Therapeutics Inc. has a market capitalization of $322.76M, 53.88M shares outstanding, 98 institutional holders tracked. Key dilution vectors include approximately 22 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
42
💰 Cash Runway
25
📊 Float Risk
45
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for DMAC.
🔔 Track DMAC — Get forecast alerts →

💹 Market Data

Market Cap$322.76M
Shares Outstanding53.88M
Float28.60M
Cash$51.33M
DebtN/A
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 9.3% shares (2026Q1 vs prior)
98 institutional holders · 13.52M shares
#1 COOPERMAN LEON G 2.02M shares
#2 BlackRock, Inc. 1.86M shares
#3 MORGAN STANLEY 1.23M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest5.21M
Days to Cover17.7
% of Float18.2%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Jul 07, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for DMAC Shareholders

DiaMedica Therapeutics Inc. (DMAC) has a DilutionScore of 45/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for DMAC shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for DMAC in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for DMAC alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track DMAC Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking DMAC — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for DMAC
📊 DMAC FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 DMAC Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.